SCHEMBL6317490

SCHEMBL6317490

CCOC(=O)c1cn(C)c2c(C)csc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.47
BAZ2A Q9UIF9 1/20 0.47
TDP1 Q9NUW8 1/20 0.42
STAT3 P40763 1/20 0.41
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.38
HSD17B10 Q99714 4/20 0.38
HPGD P15428 3/20 0.38
RECQL P46063 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 2/20 0.37
GLA P06280 1/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9834486 0.86 BAZ2B (0.44) BAZ2BBAZ2ATDP1STAT3KDM4E
SCHEMBL6318668 0.85 BAZ2B (0.43) BAZ2BBAZ2ATDP1STAT3KDM4E
SCHEMBL6318082 0.76 ALDH1A1 (0.47) BAZ2BBAZ2ATDP1STAT3KDM4E
SCHEMBL6050604 0.76 BAZ2B (0.47) BAZ2BBAZ2ATDP1KDM4EALDH1A1
SCHEMBL6317607 0.74 BAZ2B (0.43) BAZ2BBAZ2ATDP1STAT3KDM4E
SCHEMBL9837365 0.73 BAZ2B (0.53) BAZ2BBAZ2ASTAT3KDM4EALDH1A1
SCHEMBL28346320 0.71 BAZ2B (0.51) BAZ2BBAZ2ATDP1STAT3KDM4E
SCHEMBL359436 0.71 CYP1A2 (0.56) KDM4EALDH1A1CYP1A2TSHRHSD17B10
SCHEMBL9835705 0.71 BAZ2B (0.54) BAZ2BBAZ2ASTAT3KDM4EALDH1A1
SCHEMBL9837457 0.71 TSHR (0.35) BAZ2BBAZ2AKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 BAZ2B 2933/4885BAZ2A 3156/4885TDP1 4046/4885
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 BAZ2B 3271/4885BAZ2A 3412/4885TDP1 704/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR BAZ2B 2954/4885BAZ2A 3187/4885TDP1 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.